{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"13"}]}],"title":"Partial Remission"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"6"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"8"}]}],"title":"Very Good Partial Remission"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"9"}]}],"title":"Minimal Residual Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"}]}],"title":"Stringent Complete Remission"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"7"}]}],"title":"Non Evaluable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"7"}]}],"title":"Stable Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"49"}],"units":"Participants"}],"description":"To determine the best overall response (CR+VGPR+PR) of the lenalidomide, thalidomide, dexamethasone combination based on IMWG criteria at nadir.","groups":[{"description":"Oral Revlimid 15mg, Thalidomide 100mg, Dexamethasone 40mg\\*21 days+ 7 days rest and reevaluation=28 day cycle","id":"OG000","title":"RTD (Cohort 1, Phase 1)"},{"description":"Oral Revlimid 25mg, Thalidomide 100mg, Dexamethasone \\*21 days+ 7 days rest and reevaluation=28 day cycle","id":"OG001","title":"RTD (Cohort 2, Phase 1)"},{"description":"Oral Revlimid 25mg, Thalidomide 200mg, Dexamethasone 40mg\\*21 days+ 7 days rest and reevaluation=28 day cycle","id":"OG002","title":"RTD (Cohort 3, Phase 1)"},{"description":"Oral Revlimid 25mg, Thalidomide 100mg, Dexamethasone \\*21 days+ 7 days rest and reevaluation=28 day cycle","id":"OG003","title":"RTD (Cohort 2, Phase 2)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Evaluated each 28-day cycle and nadir of criteria is considered best overall response (median time to best response for this study was 2 cycles (range for best overall response was 1-21 cycles).","title":"Complete Response(CR) and Very Good Partial Response(VGPR)","type":"PRIMARY","unitOfMeasure":"Participants"}